Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06604533 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

StatusRecruiting
PhaseNot applicable
Started2025-07-07
View on ClinicalTrials.gov ↗
The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.

Amendment record

Amended 4 times since 2024-09-17; most recent filed 2026-05-05. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-05-05
Amendment Study Status, Contacts/Locations v4
2025-11-13
Amendment Study Status, Study Design v3
2025-07-09
Amendment Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v2
2024-09-18
Amendment Study Status v1
2024-09-17
Original filing
Trial Details
NCT Number NCT06604533
Lead Sponsor Australasian Gastro-Intestinal Trials Group
Collaborators: Trans Tasman Radiation Oncology Group
Conditions Abdominal Cancer
Enrollment 30 participants
Start Date 2025-07-07
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-08